NuCana (NCNA) Share-based Compensation (2017 - 2025)
NuCana's (NCNA) quarterly Share-based Compensation came in at $1.2 million in Q4 2025, up 4467.5% year-on-year from $25773.3 in Q4 2024, and down 2.63% quarter-over-quarter from $1.2 million in Q3 2025.
NuCana (NCNA) Share-based Compensation (2017 - 2025) Analysis & Trends
NuCana has disclosed Share-based Compensation across 9 years of filings, most recently posting $1.2 million for Q4 2025.
- Share-based Compensation for Q4 2025 came in at $1.2 million, up 4467.5% year-over-year; the trailing twelve-month figure through Dec 2025 was $2.8 million (up 35.87% YoY), and the FY2025 annual result was $13.2 million, up 528.41% from the prior year.
- Share-based Compensation came in at $1.2 million for Q4 2025 at NuCana, down from $1.2 million in the prior quarter.
- In the past five years, Share-based Compensation ranged from a high of $2.5 million in Q2 2021 to a low of -$26953.5 in Q4 2024.
- The 5-year median for Share-based Compensation is $1.3 million (2025), against an average of $1.4 million.
- Across the five-year window, Share-based Compensation plunged 102.77% in 2024 and jumped 4467.5% in 2025, its largest moves.
- NuCana's Share-based Compensation stood at $2.4 million in 2021, then slumped by 37.58% to $1.5 million in 2022, then tumbled by 33.73% to $973063.1 in 2023, then slumped by 102.77% to -$26953.5 in 2024, then surged by 4467.5% to $1.2 million in 2025.
- The last three Share-based Compensation figures came in at $1.2 million (Q4 2025), $1.2 million (Q3 2025), and -$26953.5 (Q4 2024), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Share-based Compensation (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 723,416.35 Bn | 723,416.32 Bn | - | - |
| 2 | Belite Bio | 57,340.00 Bn | 57,340.00 Bn | - | - |
| 3 | Quantum Biopharma | 19,125.08 Bn | 19,125.08 Bn | - | - |
| 4 | Legend Biotech | 3,262.00 Bn | 3,261.71 Bn | 242.10 Mn | - |
| 5 | Akari Therapeutics | 1,789.67 Bn | 1,789.67 Bn | - | 305,000.00 |
| 6 | Evaxion A | 1,480.39 Bn | 1,480.37 Bn | - | - |
| 7 | Psyence Biomedical | 241.78 Bn | 241.78 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 113.54 Bn | 106.29 Bn | 2.59 Bn | 166.40 Mn |
| 9 | Abivax | 94.26 Bn | 94.26 Bn | - | 26.47 Mn |
| 10 | NuCana | 29.13 Bn | 29.13 Bn | - | 1.18 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 1.18 Mn |
| Dec 31, 2025 | 1.18 Mn |
| Sep 30, 2025 | 1.21 Mn |
| Sep 30, 2025 | 1.21 Mn |
| Dec 31, 2024 | -26,953.54 |
| Dec 31, 2024 | -26,953.54 |
| Sep 30, 2024 | 487,237.56 |
| Sep 30, 2024 | 487,237.56 |
| Jun 30, 2024 | 840,639.02 |
| Jun 30, 2024 | 840,639.02 |
| Mar 31, 2024 | 794,092.38 |
| Mar 31, 2024 | 794,092.38 |
| Dec 31, 2023 | 973,063.08 |
| Dec 31, 2023 | 973,063.08 |
| Sep 30, 2023 | 1.11 Mn |
| Sep 30, 2023 | 1.11 Mn |
| Jun 30, 2023 | 1.32 Mn |
| Jun 30, 2023 | 1.32 Mn |
| Mar 31, 2023 | 1.39 Mn |
| Mar 31, 2023 | 1.39 Mn |